AP
Apogee Therapeutics, Inc.
APGE · NASDAQ
$135.07 +0.01% (+$0.01)
1M +0.21%
Market Cap $8.36B
P/E Ratio -
Div. Yield -
ROE 29.88%
Piotroski F-Score Weak
2/9Valuation
13 /100
Expensive P/B 7.00x
EV/EBITDA N/A
P/S N/A
Growth
100 /100
Growing Book val. growth 85.30%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 29.88%
ROA 22.04%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 26.44x
Int. coverage -185.14x
Debt/Equity 0.01x
Stability
33 /100
Unstable EPS volatility 44.58%
Profitable years 0
Beta 0.34x
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre APGE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Thomas Henderson
Employees
261
Headquarters
Waltham
Evenimente viitoare
09 NOV.
Earnings
Upcoming earnings report